InsiderPulse
Dashboard

RYTM

Rhythm Pharmaceuticals, Inc.

Health CareRussell 2000

Rhythm Pharmaceuticals, Inc. insider trading

Rhythm Pharmaceuticals, Inc. files with the SEC as a Pharmaceutical Preparations company headquartered in Boston, MA. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent RYTM insider transactions

8 insiders traded RYTM on the open market between Feb 19, 2026 and Sep 14, 2026 — 24 sales worth $33.6M, of which 22 were pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$33.6M

22 of 24 on a 10b5-1 plan

Net
−$33.6M
Insiders
8

Open-market purchases (code P) and sales (code S) from Rhythm Pharmaceuticals, Inc.'s own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 23, 2026. The live dashboard shows new filings the moment they clear.

Every RYTM Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

RYTM insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 11 insiders traded RYTM on the open market: 0 purchases and 131 sales worth $58.1M, 122 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 54 sales ($24M), by 6 insiders.

QuarterBoughtSold
Q2 2026—−$4.1M2 sales · 1 on a plan
Q1 2026—−$2.7M24 sales · 23 on a plan
Q4 2025—−$6.1M9 sales · all on a plan
Q3 2025—−$11.1M19 sales · all on a plan
Q2 2025—−$12.4M16 sales · all on a plan
Q1 2025—−$6.3M35 sales · 28 on a plan
Q4 2024—−$5.9M9 sales · all on a plan
Q3 2024—−$9.4M17 sales · all on a plan
Largest sale
−$3.7M of RYTM by Tetrault Lynn A. (Director) on Jun 22, 2026, under a 10b5-1 plan.

Open-market transactions through Jun 30, 2026most recent first

  • Tetrault Lynn A.10b5-1

    Director

    −$3.7M

    Jun 22, 2026

    37,000 sh · $100.32

  • Smith Hunter C10b5-1

    Chief Financial Officer

    −$170.8K

    Feb 19, 2026

    1,692 sh · $100.92

  • Smith Hunter C10b5-1

    Chief Financial Officer

    −$81.7K

    Feb 19, 2026

    800 sh · $102.10

  • Smith Hunter C10b5-1

    Chief Financial Officer

    −$60.4K

    Feb 19, 2026

    585 sh · $103.28

  • Smith Hunter C10b5-1

    Chief Financial Officer

    −$119.3K

    Feb 17, 2026

    1,200 sh · $99.42

  • Smith Hunter C10b5-1

    Chief Financial Officer

    −$110.1K

    Feb 17, 2026

    1,069 sh · $103.00

  • Smith Hunter C10b5-1

    Chief Financial Officer

    −$91.5K

    Feb 17, 2026

    900 sh · $101.70

  • Smith Hunter C10b5-1

    Chief Financial Officer

    −$20.8K

    Feb 17, 2026

    200 sh · $103.84

  • Smith Hunter C10b5-1

    Chief Financial Officer

    −$20.1K

    Feb 17, 2026

    200 sh · $100.52

  • Smith Hunter C10b5-1

    Chief Financial Officer

    −$79.2K

    Feb 12, 2026

    800 sh · $98.99

  • Smith Hunter C10b5-1

    Chief Financial Officer

    −$39.1K

    Feb 12, 2026

    400 sh · $97.67

  • Smith Hunter C10b5-1

    Chief Financial Officer

    −$28.1K

    Feb 12, 2026

    292 sh · $96.26

  • Smith Hunter C10b5-1

    Chief Financial Officer

    −$10K

    Feb 12, 2026

    100 sh · $100.10

  • Smith Hunter C10b5-1

    Chief Financial Officer

    −$222.9K

    Feb 11, 2026

    2,266 sh · $98.37

  • Smith Hunter C10b5-1

    Chief Financial Officer

    −$39.8K

    Feb 11, 2026

    400 sh · $99.44

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Rhythm Pharmaceuticals, Inc. company record

SEC industry classification
Pharmaceutical Preparations
Headquarters
Boston, MA
Incorporated in
DE
Listed on
Nasdaq
SEC Central Index Key
0001649904
Previously filed as
RHYTHM METABOLIC, INC.

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought RYTM

What the stock actually did in the 90 days following each open-market purchase

Don't check RYTM — let it ping you

Get told the moment an insider moves on RYTM

Pro watches Rhythm Pharmaceuticals, Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add RYTM to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track RYTM on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read RYTM insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

SMMTSNDXSRRKTGTXVERAVKTXXENEZLABATTODNTHUTHRCORT
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are RYTM insiders buying or selling?
Between Feb 19, 2026 and Sep 14, 2026, 8 Rhythm Pharmaceuticals, Inc. insiders made no open-market purchases and 24 sales worth $33.6M, a net sale of $33.6M. 22 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much RYTM stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 11 Rhythm Pharmaceuticals, Inc. insiders made no open-market purchases and 131 sales worth $58.1M. 122 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 54 sales ($24M). The largest sale was Tetrault Lynn A. selling $3.7M on Jun 22, 2026.
What was the largest recent RYTM insider trade?
Lee Jennifer Kayden (EVP, Head of North America) sold $8.9M of RYTM stock on Aug 13, 2026 at about $117.38 a share, under a pre-scheduled 10b5-1 plan.
When did an insider last buy RYTM shares?
No open-market purchase by a Rhythm Pharmaceuticals, Inc. insider appears in the filings from Feb 19, 2026 to Sep 14, 2026 — every recorded open-market transaction in that period was a sale.
Where does RYTM insider trading data come from?
From the Form 4 filings Rhythm Pharmaceuticals, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.